Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon...
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
...
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2013-04-29
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT00068653
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT00068432
- Locations
- 🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States
🇺🇸M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT
- Conditions
- Interventions
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2015-03-18
- Target Recruit Count
- 35
- Registration Number
- NCT00068770
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus
- Conditions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2009-12-08
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 39
- Registration Number
- NCT00066716
- Locations
- 🇺🇸
New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
Treatment of Diabetic Nephropathy
- Conditions
- First Posted Date
- 2003-07-31
- Last Posted Date
- 2010-01-14
- Target Recruit Count
- 30
- Registration Number
- NCT00065559
- Locations
- 🇺🇸
Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs
- Conditions
- First Posted Date
- 2003-07-18
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 138
- Registration Number
- NCT00065169
- Locations
- 🇺🇸
UCLA Neuropsychiatric Institute, Los Angeles, California, United States
Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 86
- Registration Number
- NCT00064181
- Locations
- 🇪🇬
National Cancer Institute - Cairo, Cairo, Egypt
🇭🇺National Institute of Oncology, Budapest, Hungary
🇩🇪Westpfalz-Klinikum GmbH, Kaiserslautern, Germany
Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer
- Conditions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2014-02-11
- Target Recruit Count
- 25
- Registration Number
- NCT00061906
- Locations
- 🇺🇸
Ohio State University Comrehensive Cancer Center, Columbus, Ohio, United States
🇺🇸University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 38
- Registration Number
- NCT00061893
- Locations
- 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, Huntington, West Virginia, United States
Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT00062179
- Locations
- 🇺🇸
New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
🇺🇸Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.